Evidence map›Paper›PMID 36360312›Full record

ArticleGenes2022

Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors.

Laila C Schenkel, Joseph Mathew, Hal Hirte, John Provias, Guillaume Paré, Michael Chong, Daria Grafodatskaya, Elizabeth McCready

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Laila C SchenkelFaculty of Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
Joseph MathewFaculty of Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
Hal HirteFaculty of Health Sciences, Department of Oncology, McMaster University, 699 Concession Street, Hamilton, ON L8V 5C2, Canada.ORCID 0000-0003-2888-4146
John ProviasFaculty of Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
Guillaume ParéFaculty of Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
Michael ChongFaculty of Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
Daria GrafodatskayaFaculty of Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
Elizabeth McCreadyFaculty of Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.ORCID 0000-0002-7952-2279
Hamilton Regional Laboratory Medicine Program · CAMcMaster University · CAPopulation Health Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular biomarkers, such as

methodsWhole-genome methylation array (WGMA) testing was performed using 48 glioma DNA samples to detect methylation aberrations and chromosomal gains and losses. The analyzed samples include 39 tumors in the discovery cohort and 9 tumors in the replication cohort. Methylation profiles for each sample were correlated with IDH1 p.R132G mutation, immunohistochemistry (IHC), and previous 1p19q clinical testing to assess the sensitivity and specificity of the WGMA assay for the detection of these variants.

resultsWe developed a DNA methylation signature to specifically distinguish a

conclusionsThe DNA methylation signature presented here has the potential to refine the utility of WGMA to predict

Indexed as

Brain NeoplasmsGliomaDNA Copy Number VariationsDNA MethylationHumansIsocitrate DehydrogenaseMutationIDH1 protein, humanIsocitrate Dehydrogenase1p19q co-deletiongliomaIDH1/IDH2 epi-signaturewhole-genome methylation array

Identifiers

PMID36360312
PMCPMC9690723
OpenAlexW4308869288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.